Beta Bionics CFO sells 6,675 shares for taxes
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Beta Bionics, Inc. (BBNX) reported that Chief Financial Officer Stephen Feider sold 6,675 shares of common stock on September 2, 2026 at a weighted average price of $19.1131 per share, with prices ranging from $18.89 to $19.545, to cover tax withholding obligations from vesting restricted stock units, and now holds 159,378 shares directly. No Rule 10b5-1 trading plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 6,675 | $19.1131 | $128K |
Footnotes (2)
- F1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- F2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Key Figures
Key Terms
restricted stock units financial
tax withholding obligations financial
weighted average sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BBNX report for its CFO?
Was the BBNX CFO’s sale made under a Rule 10b5-1 trading plan?
How large was the net insider selling by the BBNX CFO in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.